CompletedPhase 2NCT02484430
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Aref Al-KaliMayo Clinic Cancer Center LAO
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2024
Study locations (14)
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02484430 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University